114798-36-6 Usage
Description
Losartan Carboxaldehyde is an intermediate aldehyde metabolite of the angiotensin II type 1 receptor antagonist, losartan. It is a yellow solid that does not block angiotensin receptors but inhibits endothelial cyclooxygenase (COX)-2 expression, thereby exerting anti-inflammatory actions. It has also been shown to block the upregulation of intercellular adhesion molecule (ICAM)-1 mRNA and COX-dependent generation of thromboxane A2 and prostaglandin F2α. Additionally, Losartan Carboxaldehyde can act as a partial agonist of the insulin-sensitizing peroxisome proliferator-activated receptor γ in vitro.
Uses
Used in Pharmaceutical Industry:
Losartan Carboxaldehyde is used as an intermediate in the synthesis of EXP 3174, a metabolite of Losartan. It plays a crucial role in the development of new drugs and therapies.
Used in Anti-inflammatory Applications:
Losartan Carboxaldehyde is used as an anti-inflammatory agent due to its ability to inhibit COX-2 expression, which contributes to its anti-inflammatory properties.
Used in Insulin Sensitization:
Losartan Carboxaldehyde is used as a partial agonist of the insulin-sensitizing peroxisome proliferator-activated receptor γ, which can be beneficial in the treatment of conditions related to insulin resistance.
in vitro
losartan is an intermediate aldehyde metabolite of losartan, the angiotensin ii type 1 receptor antagonist. losartan could not block angiotensin receptors, but inhibit the expression of endothelial cyclooxygenase (cox)-2, therefore exerting anti-inflammatory actions. moreover, losartan at 1 μm was able to block the upregulation of icam-1 mrna and cox-dependent generation of thromboxane a2 and prostaglandin f2α [1].
in vivo
in animal stufdy, losartan was infused for 10 days to rats on a normal sodium intake (nna) and rats on a high sodium intake (hna) to suppress endogenous ang ii. although basal plasma renin activity was markedly suppressed in hna rats compared with nna rats, control arterial pressure was not different between nna and hna rats. losartan could decrease arterial pressure from control levels in nna rats on the first day of infusion but had no effect on arterial pressure in hna rats. in addition, by day 10 of losartan infusion, arterial pressure had decreased further from control levels in nna rats but remained unchanged compared with control in hna rats [2].
references
[1] c. kr mer, j. sunkomat, j. witte, et al. angiotensin ii receptor-independent antiinflammatory and antiaggregatory properties of losartan: role of the active metabolite exp3179. circulation research 90(7), 770-776 (2002).[2] collister jp, hornfeldt bj, osborn jw. hypotensive response to losartan in normal rats. role of ang ii and the area postrema. hypertension. 1996 mar;27(3 pt 2):598-606.[3] goa kl, wagstaff aj. losartan potassium: a review of its pharmacology, clinical efficacy and tolerability in the management of hypertension. drugs. 1996 may;51(5):820-45.
Check Digit Verification of cas no
The CAS Registry Mumber 114798-36-6 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 1,1,4,7,9 and 8 respectively; the second part has 2 digits, 3 and 6 respectively.
Calculate Digit Verification of CAS Registry Number 114798-36:
(8*1)+(7*1)+(6*4)+(5*7)+(4*9)+(3*8)+(2*3)+(1*6)=146
146 % 10 = 6
So 114798-36-6 is a valid CAS Registry Number.
114798-36-6Relevant articles and documents
Oxidative degradation of the antihypertensive drug losartan by alkaline copper(III) periodate complex in the presence and absence of ruthenium(III) catalyst: a kinetic and mechanistic study of losartan metabolite
Bolattin, Mallavva B.,Meti, Manjunath D.,Nandibewoor, Sharanappa T.,Chimatadar, Shivamurti A.
, p. 1649 - 1663 (2015)
Spectrophotometric kinetic technique has been used to study the oxidation of losartan by diperiodatocuprate(III) (DPC) in the presence and absence of ruthenium(III) catalyst in aqueous alkaline medium at constant ionic strength of 0.90 mol dm-3
A convenient synthesis by microwave irradiation of an active metabolite (EXP-3174) of losartan
Santagada, Vincenzo,Fiorino, Ferdinando,Perissutti, Elisa,Severino, Beatrice,Terracciano, Sara,Teixeira, Cleber Evandro,Caliendo, Giuseppe
, p. 1149 - 1152 (2003)
A novel and convenient microwave-assisted synthesis of an active metabolite (EXP-3174) of losartan is described. Room temperature and microwave irradiation of the reactions are compared. Synthesis by microwave irradiation gave the desired compound in higher yields and in shorter reaction times than those obtained at room temperature.
Preparing method for EXP-3174
-
Paragraph 0015, (2016/10/09)
The invention discloses a preparing method for EXP-3174. The preparing method is characterized in that losartan is used as a starting raw material and is prepared into EXP-3174 through two-step oxidation. The preparing method has the greatest advantages that a reaction is moderate, the number of side reactions is small, aftertreatment is simple, and EXP-3174 with the purity of 99.9% can be obtained without column chromatography isolation.